Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19). These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
Size: 686 KB